Free Trial
TSE:ONC

Oncolytics Biotech (ONC) Stock Price, News & Analysis

Oncolytics Biotech logo
C$0.82 +0.05 (+6.49%)
As of 04/29/2025 04:00 PM Eastern

About Oncolytics Biotech Stock (TSE:ONC)

Key Stats

Today's Range
C$0.78
C$0.84
50-Day Range
C$0.70
C$1.09
52-Week Range
C$0.67
C$2.08
Volume
39,300 shs
Average Volume
98,256 shs
Market Capitalization
C$63.20 million
P/E Ratio
N/A
Dividend Yield
0.31%
Price Target
C$3.50
Consensus Rating
N/A

Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

ONC MarketRank™: 

Oncolytics Biotech scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncolytics Biotech is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncolytics Biotech is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oncolytics Biotech has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ONC.
  • Dividend Yield

    Oncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Oncolytics Biotech does not have a long track record of dividend growth.

  • Read more about Oncolytics Biotech's dividend.
  • Short Interest

    There is no current short interest data available for ONC.
  • Search Interest

    3 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.82% of the stock of Oncolytics Biotech is held by insiders.

  • Percentage Held by Institutions

    Only 1.75% of the stock of Oncolytics Biotech is held by institutions.

  • Read more about Oncolytics Biotech's insider trading history.
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

Top performing AI play of the decade…? (The answer will shock you)
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Oncolytics Biotech Inc.
Oncolytics price target lowered to C$5 from C$6 at RBC Capital
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

Oncolytics Biotech's stock was trading at C$1.33 at the beginning of 2025. Since then, ONC stock has decreased by 38.3% and is now trading at C$0.82.
View the best growth stocks for 2025 here
.

Oncolytics Biotech Inc. (TSE:ONC) posted its earnings results on Tuesday, November, 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01.

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), (ONCYF) (ONCYF), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and Barrick Gold (GOLD).

Company Calendar

Last Earnings
11/12/2024
Today
4/30/2025

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:ONC
CIK
N/A
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$3.50
High Stock Price Target
C$3.50
Low Stock Price Target
C$3.50
Potential Upside/Downside
+326.8%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-27,662,548.23
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.19 per share
Price / Cash Flow
4.22
Book Value
C$0.12 per share
Price / Book
6.97

Miscellaneous

Free Float
N/A
Market Cap
C$63.20 million
Optionable
Not Optionable
Beta
1.35
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (TSE:ONC) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners